{"id":95,"date":"2014-11-05T12:37:34","date_gmt":"2014-11-05T12:37:34","guid":{"rendered":"http:\/\/delveinsightblog.wordpress.com\/?p=95"},"modified":"2025-05-02T16:29:14","modified_gmt":"2025-05-02T10:59:14","slug":"global-hemophilia-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market","title":{"rendered":"Global Hemophilia Market"},"content":{"rendered":"

\"\"<\/p>\n

\n

Get Market Intelligence of Hemophilia Market with DelveInsight<\/strong><\/em><\/p>\n<\/blockquote>\n

The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor.<\/p>\n

Currently about 20,000 people have hemophilia in the US; about 80% of them have hemophilia A, and 3,000 to 4,000 have hemophilia B. About 400 US babies with hemophilia are born each year. Von Willebrand disease is the most common bleeding disorder, affecting about 1% of the population.<\/p>\n

In the Haemophilia world; diseases are cured by factors like Hemophilia A patients use factor VIII (FVIII), Hemophilia B patients use factor IX (FIX) and VWD patients use factor VIII with VWF (VWF\/FVIII complex).<\/p>\n

Long Acting Treatments<\/strong>\u00a0<\/span><\/p>\n

The Recombinant hemophilia market is set to take over the market place with the long acting treatments in the major markets; the US, France, Germany, Italy, Spain, UK and Japan by the beginning in the US in 2014 and the European countries (5EU) in 2015.\u00a0The launch of Biogen Idec and Sobi\u2019s long-acting therapies for hemophilia A and B will affect the position of Baxter, Bayer and Pfizer\u2019s market- leading therapies. These long acting therapies will give a significant increase in sales to the hemophilia market.
\nUnderstand Haemophilia Market<\/strong>\u00a0<\/span>with our Reports. Get the deeper understanding of the long-acting recombinant factor VIII and factor IX therapies and its impact on the on current treatments for hemophilia A and B and VWD. Global sales forecasting of the Hemophilia Market till 2016 for the individual marketed products. Get access over pipeline drugs, the technology, stage of development, their targets, mechanism of action with our Pipeline reports.<\/p>\n

Contact Us at\u00a0<\/span>info@delveinsight.com<\/a><\/strong>\u00a0<\/span>
\nOur reports can be customized to include any specific information that you might interested in. Send us an email with your requirements and our team will get back to you instantly.<\/p>\n","protected":false},"excerpt":{"rendered":"

Get Market Intelligence of Hemophilia Market with DelveInsight The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor. Currently about 20,000 people have hemophilia in the US; about 80% of them have hemophilia A, and 3,000 to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[92,106,107,114,122,134,178,179,192,204,213,216,284,285,286,360,374,377,388,460,477,542,604],"industry":[17225],"therapeutic_areas":[17233,17234],"class_list":["post-95","post","type-post","status-publish","format-standard","hentry","category-articles","tag-asia","tag-baxter","tag-bayer","tag-biogen-idec","tag-blockbuster-drugs","tag-business-consultant","tag-company-overview","tag-company-profiling","tag-csl-limited","tag-delveinsight","tag-discovery","tag-drug","tag-hemophilia-a","tag-hemophilia-b","tag-hemophilia-market","tag-long-acting-treatments","tag-market-forecasting","tag-market-increase","tag-marketed-drugs","tag-pfizer","tag-pipeline","tag-sobi","tag-von-willebrand-disease","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nGlobal Hemophilia Market - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Hemophilia Market - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-11-05T12:37:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-02T10:59:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ci5.googleusercontent.com\/proxy\/Pc3omC3qiUT9SI2su-5bQta-y0ENFWw50FWs4O9ycVWCHZzlnCndRIebE9aCLxUGUV_CFUQSixDXpCs1Bfon7XS0QN_i1SDNGeo89obmfagpuVXo=s0-d-e1-ft#http:\/\/images.benchmarkemail.com\/client426691\/image1623164.png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Global Hemophilia Market - DelveInsight Business Research","description":"The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market","og_locale":"en_US","og_type":"article","og_title":"Global Hemophilia Market - DelveInsight Business Research","og_description":"The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD)","og_url":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2014-11-05T12:37:34+00:00","article_modified_time":"2025-05-02T10:59:14+00:00","og_image":[{"url":"https:\/\/ci5.googleusercontent.com\/proxy\/Pc3omC3qiUT9SI2su-5bQta-y0ENFWw50FWs4O9ycVWCHZzlnCndRIebE9aCLxUGUV_CFUQSixDXpCs1Bfon7XS0QN_i1SDNGeo89obmfagpuVXo=s0-d-e1-ft#http:\/\/images.benchmarkemail.com\/client426691\/image1623164.png","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market","url":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market","name":"Global Hemophilia Market - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market#primaryimage"},"thumbnailUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/Pc3omC3qiUT9SI2su-5bQta-y0ENFWw50FWs4O9ycVWCHZzlnCndRIebE9aCLxUGUV_CFUQSixDXpCs1Bfon7XS0QN_i1SDNGeo89obmfagpuVXo=s0-d-e1-ft#http:\/\/images.benchmarkemail.com\/client426691\/image1623164.png","datePublished":"2014-11-05T12:37:34+00:00","dateModified":"2025-05-02T10:59:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD)","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/global-hemophilia-market#primaryimage","url":"https:\/\/ci5.googleusercontent.com\/proxy\/Pc3omC3qiUT9SI2su-5bQta-y0ENFWw50FWs4O9ycVWCHZzlnCndRIebE9aCLxUGUV_CFUQSixDXpCs1Bfon7XS0QN_i1SDNGeo89obmfagpuVXo=s0-d-e1-ft#http:\/\/images.benchmarkemail.com\/client426691\/image1623164.png","contentUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/Pc3omC3qiUT9SI2su-5bQta-y0ENFWw50FWs4O9ycVWCHZzlnCndRIebE9aCLxUGUV_CFUQSixDXpCs1Bfon7XS0QN_i1SDNGeo89obmfagpuVXo=s0-d-e1-ft#http:\/\/images.benchmarkemail.com\/client426691\/image1623164.png"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Asia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Baxter<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biogen Idec<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Blockbuster drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Company Overview<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">company profiling<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CSL Limited<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hemophilia A<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hemophilia B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hemophilia Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Long Acting Treatments<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Forecasting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Increase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Marketed drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sobi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Von Willebrand disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Asia<\/span>","<span class=\"advgb-post-tax-term\">Baxter<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Biogen Idec<\/span>","<span class=\"advgb-post-tax-term\">Blockbuster drugs<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">Company Overview<\/span>","<span class=\"advgb-post-tax-term\">company profiling<\/span>","<span class=\"advgb-post-tax-term\">CSL Limited<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Discovery<\/span>","<span class=\"advgb-post-tax-term\">Drug<\/span>","<span class=\"advgb-post-tax-term\">hemophilia A<\/span>","<span class=\"advgb-post-tax-term\">hemophilia B<\/span>","<span class=\"advgb-post-tax-term\">Hemophilia Market<\/span>","<span class=\"advgb-post-tax-term\">Long Acting Treatments<\/span>","<span class=\"advgb-post-tax-term\">Market Forecasting<\/span>","<span class=\"advgb-post-tax-term\">Market Increase<\/span>","<span class=\"advgb-post-tax-term\">Marketed drugs<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Sobi<\/span>","<span class=\"advgb-post-tax-term\">Von Willebrand disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Nov 5, 2014","modified":"Updated on May 2, 2025"},"absolute_dates_time":{"created":"Posted on Nov 5, 2014 12:37 pm","modified":"Updated on May 2, 2025 4:29 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/95","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=95"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/95\/revisions"}],"predecessor-version":[{"id":31601,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/95\/revisions\/31601"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=95"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=95"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=95"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=95"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=95"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}